Patents by Inventor Daniel E. Cohen

Daniel E. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10457715
    Abstract: Provided herein are variants of an archaerhodopsin useful for application such as optical measurement of membrane potential. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, cells comprising the polynucleotides, and cells comprising the polypeptides; and methods of using the variants.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 29, 2019
    Assignees: President and Fellows of Harvard College, The Governors of the University of Alberta
    Inventors: Adam E. Cohen, Daniel Hochbaum, Peng Zou, Samouil Leon Farhi, Robert Earl Campbell, Yongxin Zhao, Daniel Jed Harrison
  • Publication number: 20190290940
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.
    Type: Application
    Filed: June 7, 2019
    Publication date: September 26, 2019
    Applicant: CoLabs International Corporation
    Inventors: Daniel H. Traynor, Laura E. Cohen
  • Patent number: 10421070
    Abstract: Embodiments of the present invention relate to methods and apparatuses for the discretization and manipulation of sample volumes that is simple, robust, and versatile. It is a fluidic device that partitions a sample by exploiting the interplay between fluidic forces, interfacial tension, channel geometry, and the final stability of the formed droplet and/or discretized volume. These compartmentalized volumes allow for isolation of samples and partitioning into a localized array that can subsequently be manipulated and analyzed.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 24, 2019
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Daniel T. Chiu, Dawn E. Cohen, Gavin D. M. Jeffries
  • Patent number: 10392426
    Abstract: The invention, in some aspects relates to light-activated ion channel polypeptides and encoding nucleic acids and also relates in part to compositions comprising light-activated ion channel polypeptides and methods using light-activated ion channel polypeptides to alter cell activity and function.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 27, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of the University of Alberta, President and Fellows of Harvard College
    Inventors: Nathan Klapoetke, Edward Boyden, Yongku Cho, Brian Y. Chow, Gane K. S. Wong, Adam E. Cohen, Daniel R. Hochbaum
  • Publication number: 20190217289
    Abstract: Embodiments of the present invention relate to methods and apparatuses for the discretization and manipulation of sample volumes that is simple, robust, and versatile. It is a fluidic device that partitions a sample by exploiting the interplay between fluidic forces, interfacial tension, channel geometry, and the final stability of the formed droplet and/or discretized volume. These compartmentalized volumes allow for isolation of samples and partitioning into a localized array that can subsequently be manipulated and analyzed.
    Type: Application
    Filed: March 27, 2019
    Publication date: July 18, 2019
    Inventors: Daniel T. Chiu, Dawn E. Cohen, Gavin D.M. Jeffries
  • Patent number: 10322301
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a body wash, an after shower body lotion, a shampoo, a conditioner, a soap, a gel, a hand sanitizer, a cream, a spray, a mouse, a lotion, an ointment, a make-up product, a lip balm, a hair spray product, an arachnid/insect repellent or a medicinal product.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 18, 2019
    Assignee: CoLabs International Corporation
    Inventors: Daniel H. Traynor, Laura E. Cohen
  • Publication number: 20190167684
    Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Inventors: Christine A. Collins, Daniel E. Cohen, Gennadiy Koev, Preethi Krishnan, Tami J. Pilot-Matias
  • Patent number: 10299786
    Abstract: A minimally invasive suture insertion device utilizing small gage needles is provided for threading one or more sutures through subcutaneous tissue, both locally and from remote access points, to support, attach, sever, ligate or constrict tissue, vessels, ligaments, nerves or other anatomical features, or for pulling another device into position defined by a suture pathway. A manually operated suture transfer device and method are provided for use in various surgical applications. The suture transfer device operates as an instrument for inserting sutures into and through desired pathways. Tethered cannulas are coupled to the positioned sutures and dock, transversely, with a captured component having a capacity for engaging a single suture or multiple sutures, together or in turn within subcutaneous tissue from local or remote access points.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 28, 2019
    Assignee: Alpha Scientific Corporation
    Inventors: David E. Levine, Neal B. Cohen, Daniel S. Levine, Marshall S. Levine
  • Patent number: 10201541
    Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 12, 2019
    Assignee: ABBVIE INC.
    Inventors: Christine A. Collins, Daniel E. Cohen, Gennadiy Koev, Preethi Krishnan, Tami J. Pilot-Matias
  • Patent number: 10201584
    Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: February 12, 2019
    Assignee: ABBVIE INC.
    Inventors: Christine A. Collins, Daniel E. Cohen, Gennadiy Koev, Preethi Krishnan, Tami J. Pilot-Matias
  • Publication number: 20180177778
    Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.
    Type: Application
    Filed: June 28, 2016
    Publication date: June 28, 2018
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Tolga Baykal, Barry M. Bernstein, Scott c. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Lino X Rodrigues Jr., Regis A. Vilchez
  • Patent number: 9949004
    Abstract: An apparatus capable of transmitting sound and vibrations to a user is described. The apparatus may also generate an electromagnetic field sufficient to stimulate the user's energy system. The apparatus includes a support structure configured to support at least a part of the user's body; a transducer coupled to the frame of the support structure in a manner which allows the transducer to move in relation to the frame; and an audio signal source for transmitting audio signals to the transducer. The transducer is capable of receiving and responding to audio signals having a wide range of audio frequencies when the apparatus is in use.
    Type: Grant
    Filed: July 6, 2013
    Date of Patent: April 17, 2018
    Inventor: Daniel E. Cohen
  • Publication number: 20160333404
    Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Application
    Filed: December 2, 2014
    Publication date: November 17, 2016
    Inventors: Barry M. Bernstein, Isabelle A. Gaultier, Daniel E. Cohen, Jeffrey F. Waring, Stephen J. Abel, Emily O. Dumas
  • Patent number: 9452194
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 27, 2016
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
  • Publication number: 20160237491
    Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.
    Type: Application
    Filed: November 10, 2014
    Publication date: August 18, 2016
    Inventors: Daniel E. Cohen, Kenneth B. Idler, Jeffrey F. Waring, Emily O. Dumas, Sandeep Dutta
  • Publication number: 20160228496
    Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.
    Type: Application
    Filed: March 13, 2014
    Publication date: August 11, 2016
    Applicant: AbbVie Inc.
    Inventors: Daniel E. Cohen, Kenneth B. Idler, Jeffrey F. Waring, Emily O. Dumas, Sandeep Dutta
  • Publication number: 20150209403
    Abstract: This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.
    Type: Application
    Filed: January 27, 2015
    Publication date: July 30, 2015
    Inventors: Walid M. Awni, Prajakta Badri, Daniel E. Cohen, Sandeep Dutta, Amit Khatri, Rajeev M. Menon, Thomas Podsadecki, Akshanth Polepally, Roger Trinh, Tianli Wang, Jiuhong Zha
  • Publication number: 20150196615
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
  • Publication number: 20150164976
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection.
    Type: Application
    Filed: February 23, 2015
    Publication date: June 18, 2015
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
  • Patent number: 9044480
    Abstract: The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Tami Pilot-Matias, Isabelle A. Gaultier, Rakesh L. Tripathi, Christine A. Collins, Daniel E. Cohen, Barry M. Bernstein